

1. Method of inducing therapeutic tranquilization with psilocybin and psilocin

US US3192111A Hofmann Albert Sandoz Ltd

Priority 1959-02-16 • Filing 1962-05-14 • Grant 1965-06-29 • Publication 1965-06-29

2. THE METHOD OF INDUCING THERAPEUTIC TRANQUILIZATION, WHICH COMPRISES ADMINISTERING TO A PATIENT A THERAPEUTICALLY EFFECTIVE AMOUNT OF CRYSTALLINE PSILOCYBIN.

2. Obtaining psilocybin and psilocin from fungal material

US CH ES LU US3183172A Heim Roger Sandoz Ltd

Priority 1958-02-21 • Filing 1959-02-16 • Grant 1965-05-11 • Publication 1965-05-11

1. A process for obtaining the psychotropically active compounds **psilocybin and psilocin, which comprises extracting the active principles from fungal material of one of the species Psilocybe mexicana Heim, Stropharia cubensis Earle, Psilocybe semperfervida Heim and Cailleux, Psilocybe caerulescens ...**

3. A process for obtaining the novel compounds psilocybin and psilocin

AT AT211955B Sandoz Ag

Priority 1958-07-30 • Filing 1959-02-13 • Grant 1960-11-25 • Publication 1960-11-25

<Desc / CLMS Page number 1> A process for obtaining the novel compounds **Psilocybin** and psilocin. The present invention relates to a method for obtaining the previously unknown, psychotropic active compounds **psilocybin** and psilocin from fungal species. It was already known (R. Heim, C. r. Hebd.

4. Psilocybin or psilocin in combination with cannabinoid

WO NL NL2018190B1 Küçükseñ Murat Procare Beheer B V

Priority 2017-01-18 • Filing 2017-01-18 • Grant 2018-07-26 • Publication 2018-07-26

6. **psilocybin** and / or psilocin in combination with at least one cannabinoid for use according to any one of the preceding claims, wherein the at least one cannabinoid is present in a pure form. 7. **psilocybin** and / or psilocin in combination with at least one cannabinoid for use according to any ...

5. Preparation of psilocybin, different polymorphic forms, intermediates, ...

WO US GB US20190119310A1 Derek John Lonesbrough Compass Pathways Limited

Priority 2017-10-09 • Filing 2018-10-09 • Publication 2019-04-25

FIG. 8 a or 8 b. 2 . Crystalline **psilocybin** in the form Polymorph A or Polymorph A', according to claim 1 further characterised by an endothermic event in a DSC thermogram having an onset temperature of between 210 and 215° C. 3 . Crystalline **psilocybin** in the form Polymorph A, according to claim 1

6. Psilocybin and psilocin and processes for their preparation

GB GB911946A Sandoz Ltd

Priority 1958-02-21 • Filing 1959-02-11 • Publication 1962-12-05

The invention comprises the psychotropically active compounds **Psilocybin** of the formula: <FORM:0911946/IV (b)/1> and Psilocin of the formula: <FORM:0911946/IV (b)/2> and a process for their extraction from fungal material of the genera Psilocybe, Stropharia and Panaeolus or biological variants or ...

7. A process for recovering psilocybin and psilocin

CH CH377482A Hofmann Albert Sandoz Ag

Priority 1958-07-30 • Filing 1958-07-30 • Publication 1964-05-15

A process for recovering **psilocybin** and psilocin according to claim, characterized in that one uses as starting material the hat mushroom Psilocybe the genus, species Zapotecorum home

ver. 5. A process for obtaining **psilocybin** and psilocin according to claim, characterized in that as starting ...

8. Compositions and methods comprising a psilocybin derivative

WO US [US20180221396A1](#) Andrew R. Chadeayne CaaMTech, LLC

Priority 2017-02-09 • Filing 2018-02-09 • Publication 2018-08-09

, comprising a molar ratio between about 10:1 to about 1:10 of the first purified **psilocybin** derivative to the second purified **psilocybin** derivative. 3 . The composition of claim 1 , comprising a molar ratio between about 100:1 to about 1:100 of the first purified **psilocybin** derivative to the second ...

9. Process for preparing biomass containing psilocybin and psilocin from a fungus

CS [CS276073B6](#) Marta Rndr Csc Semerdzieva Mikrobiologicky Ustav Csav

Priority 1990-08-14 • Filing 1990-08-14 • Publication 1992-03-18

EE preparation solves psychotropic substances peilocybinu peilociau and culturing the fungi Psilocybe bohemica Šebek whose mycelium produces deep culturing conditions and on a liquid complex medium substantially higher concentrations of these substances. The purpose is to allow the fermentative ...

10. Psilocybin compositions

US [US20190105313A1](#) Paul Edward Stamets Paul Edward Stamets

Priority 2016-07-23 • Filing 2018-12-06 • Publication 2019-04-11

1 . A composition comprising: **psilocybin**, psilocin, baeocystin, norbaeocystin, or salts thereof, **psilocybin** mushrooms or extracts thereof, or combinations thereof; and niacin. 2 . The composition of claim 1 , wherein the composition further comprises Bacopa species (Bacopa monnieri), Gotu kola (...

11. Compositions comprising a psilocybin derivative and a cannabinoid

WO2019099745A1 Andrew CHEDEAYNE CaaMTech, LLC

Priority 2017-11-16 • Filing 2018-11-15 • Publication 2019-05-23

13. The composition of claim 11, wherein the first cannabinoid is chosen from THC, THC A, THCV, THCVA, CBC, CBCA, CBCV, CBCVA, CBD, CBDA, CBDV, CBDVA, CBG, CBGA, CBGV, or CBGVA. 14. The composition of claim 11, wherein the first **psilocybin** derivative is a purified **psilocybin** derivative. 15. The ...

12. Compositions comprising a psilocybin derivative and a cannabinoid

US US20190142851A1 Andrew R. Chadeayne CaaMTech, LLC

Priority 2017-11-16 • Filing 2018-11-15 • Publication 2019-05-16

wherein the first **psilocybin** derivative and the first purified cannabinoid are present as a homogeneous mixture within the composition. 11 . A composition comprising a first **psilocybin** derivative and a first cannabinoid. 12 . The composition of claim 11 , wherein the first **psilocybin** derivative is ...

13. A process for the extraction of psilocin and psilocybin.

DK DK98374C Sandoz Ag

Priority 1958-02-21 • Filing 1959-01-28 • Grant 1964-04-06 • Publication 1964-04-06

14. Psilocybin and psilocin

IE IE24138L Sandoz Ag

Priority 1959-02-18 • Filing 1959-02-18 • Publication 1959-08-21

15. A process for the production and recovery of psilocybin and psilocin

DE DE1087321B Roger Heim Sandoz Ag

Priority 1958-02-21 • Filing 1959-01-31 • Publication 1960-08-18

16. Psilocybin and psilocin

CA CA672478A Heim Roger Heim Roger

Grant 1963-10-15 • Publication 1963-10-15

17. Process for obtaining psilocybin and psilocin

FR NL FR1298308A Sandoz Sa

Priority 1958-02-21 • Filing 1959-02-19 • Grant 1962-07-13 • Publication 1962-07-13

18. A process for the preparation of psilocybin and psilocin.

DK DK98552C Sandoz Ag

Priority 1958-02-21 • Filing 1959-01-28 • Grant 1964-04-27 • Publication 1964-04-27

19. Integrative fungal solutions for protecting bees

WO EP US AU CA DK EA ES PL US20150335689A1 Paul Edward Stamets Paul Edward Stamets

Priority 2000-10-04 • Filing 2015-03-08 • Publication 2015-11-26

The present invention is based on a plurality of benefits from the extracts of mycelia of individual fungal species, and mixtures of species, to provide an armamentarium of defenses

from multiple stressors in order to help bees survive a complex of symptoms collectively called colony collapse ...

20. Delivery systems for mycotechnologies, mycofiltration and mycoremediation

WO US AU CA US20050176583A1 Paul Stamets Stamets Paul E.

Priority 2001-02-20 • Filing 2003-07-07 • Publication 2005-08-11

The present invention utilizes fungal spore mass or hyphal fragments in landscaping cloths, fiber substrates, paper products, hydroseeders and agricultural equipment. The fungi may include saprophytic fungi, including gourmet and medicinal mushrooms, mycorrhizal fungi, entomopathogenic fungi, ...

21. Pharmaceutical compositions

WO EP US JP CA ES US10064856B2 Paul Bosse Local Pharma, Inc.

Priority 2008-01-09 • Filing 2017-08-22 • Grant 2018-09-04 • Publication 2018-09-04

Methods and compositions are provided which comprise effective amounts of an analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic.

22. Controlled release by shearing for stenotic lesions and thrombolysis

WO EP US CN JP KR AU CA RU JP6343147B2 ドナルド・イー・イングバー・プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ

Priority 2010-08-30 • Filing 2011-08-30 • Grant 2018-06-13 • Publication 2018-06-13

..., methoxamine, methylphenidate, metizoline, metaraminol, midodrine, naphazoline, nordefrin, norepinephrine, octodrine, ornipressin, oxymethazoline, phenyl ethanolamine, phenylephrine, phenylpropanolamine isopropylamine, phenylpropanolamine, Fe Pressin, propylhexedrine, pseudoephedrine, **psilocybin**, ...

23. Detection of abused substances and their metabolites using nucleic acid sensor ...

US [US20030224435A1](#) Scott Seiwert Scott Seiwert

Priority 2002-05-16 • Filing 2003-05-16 • Publication 2003-12-04

... , LSD (Lysergic acid diethylamide), Mannitol, Marijuana (THC), Mescaline, Methadone, Methamphetamine, Methaqualone, Methcathinone, Methylphenidate (ritalin), Morphine, Nexus (2CB), Nicotine, Opium, Oxycodone, OxyContin, PCP (phencyclidine), Peyote, Phenobarbital, Procaine, **Psilocybin, Psilocybin/** ...

24. Methods for improving secondary metabolite production in fungi

WO EP US JP AU CA [US20020128250A1](#) Robert Busby Robert Busby

Priority 1999-10-20 • Filing 2001-03-07 • Publication 2002-09-12

The invention relates to the production of secondary metabolites by fungi. More particularly, the invention relates to improvement of production of commercially important secondary metabolites by fungi. The invention provides methods for improving secondary metabolite production in a fungus, ...

25. Direct micro-patterning of lipid bilayers using UV light and selected uses ...

WO US AU [US20040180147A1](#) Atul Parikh The Regents Of The University Of California

Priority 2002-10-30 • Filing 2003-10-30 • Publication 2004-09-16

This invention provides novel methods for creation of patterned lipid bilayer membranes as well as methods for refunctionalization of such patterned membranes with selected components. Such components optionally comprise, e.g., lipid bilayer membranes (which optionally comprise specific proteins), ...

26. Personal care formulations containing alkyl ketal esters and methods of ...

WO EP US CN JP KR AU BR CA IN US9549886B2 Dorie J. Yontz Gfbiochemicals Limited

Priority 2010-05-10 • Filing 2014-11-07 • Grant 2017-01-24 • Publication 2017-01-24

Personal care formulations containing alkyl ketal esters having the structure wherein a is 0 or an integer of 1 to 12; b is 0 or 1; R 2 is a divalent C 1-8 group optionally substituted with up to 5 hydroxyl groups; and R 1 is C 1-6 alkyl.

27. Personal vaporizing device

WO EP US CN JP KR AU BR CA MX PH TW CN108712918A P.达维德森 塞基医疗有限公司

Priority 2016-01-11 • Filing 2017-01-11 • Publication 2018-10-26

According to some embodiments there is provided a device configured for releasing at least one substance from a source material, comprising: a housing; a plurality of source material sections positioned at fixed locations with respect to the housing; a plurality of airflow paths, each airflow path ...

28. Packaging of immunostimulatory substances into virus-like particles: method of ...

WO EP US CN JP AT AU CA CY DE DK ES HK US20030099668A1 Martin Bachmann Cytos Biotechnology Ag

Priority 2001-09-14 • Filing 2002-09-16 • Publication 2003-05-29

The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce ...

29. In vivo activation of antigen presenting cells for enhancement of immune ...

WO EP US JP AU CA [US20030091593A1](#) Martin Bachmann Cytos Biotechnology Ag

Priority 2001-09-14 • Filing 2002-09-16 • Publication 2003-05-15

The invention relates to the finding that stimulation of antigen presenting cell (APC) activation using substances such as anti-CD40 antibodies or DNA oligomers rich in non-methylated C and G (CpGs) can dramatically enhance the specific T cell response obtained after vaccination with recombinant ...

30. Hapten-carrier conjugates comprising virus like particles and uses thereof

WO EP US CN JP KR AU BR CA IL IN MX NZ PL RU ZA [EP2392345A2](#) Martin F. Bachmann Cytos Biotechnology AG

Priority 2002-07-18 • Filing 2003-07-18 • Publication 2011-12-07

The present invention provides compositions comprising a conjugate of a hapten with a carrier in an ordered and repetitive array, and methods of making such compositions. The conjugates and compositions of the invention comprise drugs, especially drugs of addiction such as nicotine. Compositions ...

31. Drug device configured for wireless communication

WO EP US [US10245323B2](#) Randice Lisa Altschul Pop Test Abuse Deterrent Technology Llc

Priority 2014-06-03 • Filing 2018-05-23 • Grant 2019-04-02 • Publication 2019-04-02

This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.

32. Methods for treating dependence

**WO EP US CN JP AU BR CA CO ES MX NZ PH RU SG CA2695372C Tom Woiwode
Synosia Therapeutics, Inc.**

Priority 2007-08-06 • Filing 2008-08-06 • Grant 2013-01-22 • Publication 2013-01-22

Provided are methods of treating patients suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at least one substance with Compound A. Also provided are methods of treating at least one phase of substance dependence on at least one substance in ...

33. Vaccines for prevention and treatment of addiction

WO EP US CN US20110086063A1 Ronald G. Crystal Cornell University

Priority 2008-06-04 • Filing 2009-06-04 • Publication 2011-04-14

The invention provides an adenovirus-antigen conjugate comprising an adenovirus with a coat protein and an antigen of an addictive drug conjugated to the coat protein of the adenovirus. The invention also provides an adenoviral vector comprising a nucleic acid sequence which encodes an antibody ...

34. Personal substance detection field test kit

US US9551695B2 Dalita Tomellini Lindon Group, Inc.

Priority 2012-01-24 • Filing 2013-01-23 • Grant 2017-01-24 • Publication 2017-01-24

A personal-sized, portable explosive detection field test kit (ETK) and related methods of use. Embodiments of the disclosed ETK include a case having a closing system featuring three levels of closure which retain the case cover securely in a closed position until ready for use, while being ...

35. Immunochromatography detection method and test kit of psilocin such by the ...

JP JP4174016B2 博史 北條 株式会社ピーエル

Priority 2003-07-11 • Filing 2003-07-11 • Grant 2008-10-29 • Publication 2008-10-29

(Detection of psilocin and **psilocybin** in the test sample) Providing a magic mushrooms containing psilocin and **psilocybin** as a test sample, Bunashimeji not containing any of psilocin and psilocin as a control sample, shiitake was prepared Maitake and eryngii. Each of the test and control samples, ...

36. A process for the extraction of indole alkaloids from fungal material

DD DD264023A1 Jochen Gartz Akad Wissenschaften Ddr

Priority 1987-07-17 • Filing 1987-07-17 • Publication 1989-01-18

The invention relates to a process for recovering the indole alkaloids **psilocybin**, psilocin baeocystin and by extraction of the mycelia and fruiting bodies of higher fungi. The active ingredients are applicable as model substances in neurobiological research. The alkaloids are transferred from the ...

37. Methods, devices and systems for pulmonary delivery of active agents

**WO EP US CN JP KR AU CA IL MX RU KR20170026520A 페리 데이비드손 사이키
메디컬 엘티디.**

Priority 2014-06-30 • Filing 2015-06-30 • Publication 2017-03-08

To a subject an amount of one or more drugs of the active agent vaporize one or more predetermined in the plant material there is provided a system comprising a metered dose inhaler device for pulmonary delivery, vaporized in order to vaporize the vaporizing amount predetermined in the ...

38. A process for the extraction of tryptamine derivatives by culturing higher ...

DD DD254395A1 Jochen Gartz Akad Wissenschaften Ddr

Priority 1986-12-08 • Filing 1986-12-08 • Publication 1988-02-24

The invention relates to a process for the recovery of the active ingredients **psilocybin** and psilocin by culturing the fruiting bodies of higher fungi. The active ingredients are applicable as model substances in neurobiological research. The fruiting be achieved by inoculation of an autoclaved ...

39. Patent BE575588A

BE BE575588A

----- The present invention includes: 1) A process for obtaining **psilocybin** and psilocin, hitherto unknown compounds, endowed with psycho chotropes properties, from fungi , which method is extracted by known methods, active body cryptogamic substances of natural origin of species Psilocybe, ...

40. A process for the artificial cultivation of fungal material

CH CH377483A Hofmann Albert Sandoz Ag

Priority 1958-07-30 • Filing 1958-07-30 • Publication 1964-05-15

Claim processes for the production of the fungal genera Stro- Pharia, Conocybe, Panaeolus, Amanita, Russula or its biological variants or mutants and the following types of fungi of the genus Psilocybe: Psilocybe Semperfiva Heim et Cailleux, Psilocybe caerulescens Murrill var. Mazatecorum home, ...

41. Topical compositions and methods of treatment of anorectal disorders

WO EP US CN JP KR AU BR CA IL MX RU US9072747B2 Evgenia Lozinsky Peritech Pharma Ltd.

Priority 2013-03-10 • Filing 2014-03-10 • Grant 2015-07-07 • Publication 2015-07-07

A topical anorectal composition includes trimethylsiloxysilicate; at least one surfactant selected from the group consisting of sodium lauryl sulfate, alkyl- and alkoxy-dimethicone

copoloyol, polysorbate and a combination thereof; a non-polar volatile siloxane solvent; at least 15% (w/w) water; and ...

42. **Salts of physiologically active and psychoactive alkaloids and amines ...**

US [US20080293695A1](#) David William Bristol David William Bristol

Priority 2007-05-22 • Filing 2007-05-22 • Publication 2008-11-27

Drug substances comprising a pharmaceutically acceptable organic acid addition salt 6f amine containing pharmaceutically active compounds useful for the treatment of a therapeutic ailment administration and exhibiting prophylactic properties when employed in non-therapeutic administration.

43. **Sleeve Valve**

WO EP US AU BR CA EA MX NO [US20100292448A1](#) Bjorn Hagerup Nilssen Bjorn Hagerup Nilssen

Priority 2007-04-04 • Filing 2008-04-03 • Publication 2010-11-18

An extractor and a method using the extractor for extracting active principle from solid materials using an extracting fluid, said extractor comprising among others an extractor column (1), having a first side (22), a second side (23), a top side (24), and a bottom side (25); a top plate (10) for ...

44. **Antiviral activity from medicinal mushrooms and their active constituents**

US [US9931316B2](#) Paul Edward Stamets Paul Edward Stamets

Priority 2004-01-06 • Filing 2015-09-14 • Grant 2018-04-03 • Publication 2018-04-03

Compounds having unique antiviral properties found in mushroom mycelium and their analogs are extracted, concentrated, isolated or manufactured to create compositions useful in preventing the spread and proliferation of various viruses afflicting animals, particularly viruses harming humans, pigs, ...

45. Indole compounds useful as serotonin selective agents

WO EP US JP AU CA US8071786B2 Howard P. Sard Galenea Corp.

Priority 2004-09-27 • Filing 2009-12-14 • Grant 2011-12-06 • Publication 2011-12-06

Novel indole compounds are disclosed. Also disclosed are methods for using the compounds to treat human and animal disease, pharmaceutical compositions of the compounds, and kits including the compounds.

46. Modulation of secondary metabolite production by zinc binuclear...

WO EP US AU CA US20040077039A1 Holtzman Holtzman

Priority 2000-09-19 • Filing 2001-09-19 • Publication 2004-04-22

Disclosed are methods for the modulation of secondary metabolite production by fungi through genetic manipulation of such fungi. Also disclosed are new commercial processes using ZBC proteins, or variants thereof, to significantly increase useful secondary metabolite production. Generally, the ...

47. Method For Using Exhaled Breath to Determine the Presence of Drug

WO US US20140288454A1 Frederick Mark Paz Pulmonary Analytics

Priority 2013-03-14 • Filing 2014-03-14 • Publication 2014-09-25

The present invention provides a method for determining the presence and/or the level of drug in a subject's system using exhaled breath of the subject.

48. A method for the cultivation of fungal material

AT AT215600B Sandoz Ag

Priority 1958-07-30 • Filing 1959-02-13 • Grant 1961-06-12 • Publication 1961-06-12

2. The method according to claim 1, characterized in that as starting material the hat mushroom Psilocybe mexicana home is used. 3. The method according to claim 1, characterized in that as starting material the hat mushroom Stropharia cubensis Earle, the hat mushroom Psilocybe Semperviva Heim et ...

49. Disrupted adenovirus-based vaccine against drugs of abuse

WO EP US CN [US20130011432A1](#) Ronald G. Crystal Cornell University (Cctec)

Priority 2010-03-17 • Filing 2011-03-17 • Publication 2013-01-10

The invention is directed to an adenovirus-antigen conjugate comprising (a) a disrupted adenovirus with a coat protein and (b) an antigen conjugated to the coat protein of the disrupted adenovirus, as well as a conjugate comprising (a) a disrupted adenovirus with a coat protein and (b) an antigen ...

50. Integrative fungal solutions for protecting bees and overcoming colony collapse ...

US [US20140220150A1](#) Paul Edward Stamets Paul Edward Stamets

Priority 2000-10-04 • Filing 2014-04-07 • Publication 2014-08-07

The present invention is based on a plurality of benefits from the extracts of mycelia of individual fungal species, and their mixtures, to provide an armamentarium of defenses from multiple stressors in order to help bees survive and more particularly overcome a complex of symptoms collectively ...

51. Compostions and methods for preventing and/or treating disorders associated ...

US [US8859579B2](#) Richard Andrew Sewell Richard Andrew Sewell

Priority 2008-03-21 • Filing 2009-03-20 • Grant 2014-10-14 • Publication 2014-10-14

Compounds, e.g., of formula (I) and (Ia), pharmaceutical compositions comprising the compounds and methods of using the compounds and pharmaceutical compositions for treating pain disorders, e.g., disorders associated with cephalic pain, are provided.

52. A process for preparing intermediates of hmg-coa reductase inhibitors

WO EP US JP KR ES MX KR20090018964A 히렌 간디 테바 파마슈티컬 인더스트리즈 리미티드

Priority 2007-04-18 • Filing 2008-04-18 • Publication 2009-02-24

The present invention relates to intermediates of rosuvastatin and processes for the production thereof.

53. Compositions and methods for evaluating cognitive defects

WO US US20120159656A1 David J. Gerber Galenea Corp.

Priority 2009-04-24 • Filing 2010-04-23 • Publication 2012-06-21

The present invention provides, in some aspects, methods for identifying agents useful in treating disorders or conditions associated with cognitive deficits. In some aspects, the invention provides methods for detecting a cognitive deficit in a subject.

54. Indole compounds and methods of use thereof

WO EP US JP AU CA US20090318527A1 Howard Sard Howard Sard

Priority 2008-02-11 • Filing 2009-02-11 • Publication 2009-12-24

Novel indole compounds are disclosed. Also disclosed are methods for using the compounds to treat human and animal disease, pharmaceutical compositions of the compounds, and kits including the compounds.

55. Methods for treating dependence

WO WO2010124089A2 Michael Mulqueen Synosia Therapeutics, Inc.

Priority 2009-04-22 • Filing 2010-04-22 • Publication 2010-10-28

Provided are methods of treating patients suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at least one substance with nепicastat in combination with psychosocial therapy. Also provided are methods of treating at least one phase of substance ...

56. Kit and method for detecting target material

EP US CN JP KR KR20120128440A 김성지 삼성전자주식회사

Priority 2011-05-17 • Filing 2011-05-17 • Publication 2012-11-27

The method of claim 1, wherein the compound having the zwitterions are amino acids, bisin (bicine), tree new (tricine), sulfamic acid (sulfamic acid), alkaloids (alkaloid), **psilocybin** (**psilocybin**), CUNAULT cannabinoid (quinonoid) and betaine (the kit is selected from the group consisting of ...

57. Lateral flow devices and methods of manufacture and use

US US20150056687A1 Steven Patrick Tyrrell Express Diagnostics Int'l., Inc.

Priority 2013-04-26 • Filing 2014-07-30 • Publication 2015-02-26

A lateral flow assay test device providing a structure for the lateral flow assay reactions provides for a continuous flow path of bibulous material provided in separate but contiguous regions of the device in which the bibulous layers are in fluid contact with each other thereby providing flow ...

58. Lateral flow devices and methods of manufacture and use

WO US US20160167042A1 Steven Patrick Tyrrell Express Diagnostics Int'l., Inc.

Priority 2013-07-30 • Filing 2014-07-30 • Publication 2016-06-16

A lateral flow assay test device providing a structure for the lateral flow assay reactions provides for a continuous flow path of bibulous material provided in separate but contiguous regions of the device in which the bibulous layers are in fluid contact with each other thereby providing flow ...

59. Detection of analytes including drugs

WO EP US CN US20140017803A1 Robert Deans Flir Systems, Inc.

Priority 2011-03-28 • Filing 2011-03-28 • Publication 2014-01-16

Embodiments described herein provide materials, devices, and methods relating to the determination of analytes such as drugs, toxins, explosives, other controlled substances and contraband materials, and the like. In some embodiments, the analyte may be detected in vapor phase. Some embodiments ...

60. Therapeutic Compositions and Methods

WO EP US CN US20170281652A1 Randice Lisa Altschul Pop Test Oncology Llc

Priority 2012-07-30 • Filing 2017-06-20 • Publication 2017-10-05

This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the prevention or addiction induced anxiety and withdrawal side effects as a therapeutic and in concert with a diagnostic. Such addictions could be, but are not limited to, alcohol, drugs, caffeine, ...

61. Signature of electroencephalographic oscillation

US JP JP2013233437A David J Gerber Otsuka Pharmaceut Co Ltd

Priority 2012-05-07 • Filing 2013-05-07 • Publication 2013-11-21

PROBLEM TO BE SOLVED: To provide methods for identifying and evaluating signatures in electroencephalographic oscillations that occur during onset of an exploratory activity in a subject.
SOLUTION: A method includes administering a test agent to a subject who is identified as having a cognitive ...

62. Pharmaceutical liquid adhesive compositions for treatment of anorectal ...

WO US WO2014064703A1 Evgenia LOZINSKY Peritech Pharma Ltd.

Priority 2012-10-28 • Filing 2013-10-27 • Publication 2014-05-01

The present invention provides liquid adhesive compositions comprising a silicone film forming agent, a volatile solvent and a pharmaceutically active agent, and methods for preparing said compositions. The invention further provides methods for treating anorectal disorders comprising ...

63. Compositions and methods for the treatment of chronic infections

US US8329663B2 Paul Griffin Paul Griffin

Priority 2008-01-31 • Filing 2009-01-31 • Grant 2012-12-11 • Publication 2012-12-11

The present disclosure provides compositions and methods for the treatment and elimination of chronic intracellular infections in cells or organisms. The compositions may include one or more acidic substances and one or more antimicrobial substances, administered in combination or separately. The ...

64. Portable testing system for detecting selected drugs or compounds in ...

WO US US20160077091A1 Steven Patrick Tyrrell Express Diagnostics International, Inc.

Priority 2013-04-26 • Filing 2014-04-25 • Publication 2016-03-17

Devices, methods, and systems are provided for testing for or detecting the presence of illegal or prohibited drugs, compounds or metabolites in non-controlled environments for testing using lateral flow drug test strips and a smart phone with digital imaging, data processing, data storage and ...

65. Bicarbonate as a potentiator for antimicrobial agents

WO US [US20180243333A1](#) Eric Brown McMaster University

Priority 2017-02-02 • Filing 2018-02-02 • Publication 2018-08-30

Provided herein are methods and compositions for modulating a microorganism's response to an antimicrobial agent. In one embodiment, the method comprises contacting the microorganism with an antimicrobial agent and bicarbonate. In one embodiment, provided herein are methods for treating a ...

66. [5-HT2C receptor agonists and compositions and methods of use](#)

WO EP US CN JP KR AU BR CA EA IL MX [US20180186797A1](#) Albert S. Ren Arena Pharmaceuticals, Inc.

Priority 2015-04-27 • Filing 2016-04-26 • Publication 2018-07-05

Provided in some embodiments are compounds herein. Also provided in some embodiments are methods for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine ...

67. [Pharmaceutical adhesive compositions for treatment of epistaxis and methods of ...](#)

US [US20150366798A1](#) Evgenia Lozinsky Evgenia Lozinsky

Priority 2014-06-19 • Filing 2015-05-01 • Publication 2015-12-24

The present invention provides liquid adhesive compositions including at least one silicone resin film forming agent, at least one surfactant, at least one volatile solvent, water and at least one vasoconstrictor, where the compositions are in the form of an emulsion. The invention further ...

68. [Compacting upflow extractor and method of using it](#)

WO WO2008122990A1 Arvind Mallinath Lali Almet Corporation Limited

Priority 2007-04-04 • Filing 2008-04-03 • Publication 2008-10-16

An extractor and a method using the extractor for extracting active principle from solid materials using an extracting fluid, said extractor comprising among others an extractor column (1), having a first side (22), a second side (23), a top side (24), and a bottom side (25); a top plate (10) for ...

69. Antiviral activity from medicinal mushrooms and their active constituents

WO EP US AU CA WO2016161138A1 Paul Edward STAMETS Stamets Paul Edward

Priority 2015-03-31 • Filing 2016-03-31 • Publication 2016-10-06

Compounds having unique antiviral properties found in mushroom mycelium and their analogs are extracted, concentrated, isolated, synthesized or manufactured to create compositions useful in preventing the spread and proliferation of various viruses afflicting animals, particularly viruses harming ...

70. Method for stropharia rugoso-annulata under mature rubber garden

CN CN107173054A 黄坚雄 中国热带农业科学院橡胶研究所

Priority 2017-05-27 • Filing 2017-05-27 • Publication 2017-09-19

The invention discloses a method for stropharia rugoso-annulata under a mature rubber garden. The formula comprises the following cultivation materials by dry weight ratio: 40-50% of rubber wood chips, 20-30% of gorse, 15-25% of coco coir and 5-15% of wheat bran. The method comprises the operation ...

71. Methods for treating dependence

AU AU2016208412A1 Mark Moran Biotie Therapies, Inc.

Priority 2007-08-06 • Filing 2016-07-29 • Publication 2016-08-18

Provided are methods of treating patients suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at least one substance with

Compound A. Also provided are methods of treating at least one phase of substance dependence on at least one substance in ...

72. Compositions and methods for the treatment of chronic infections

WO [WO2009097596A1](#) Paul Griffin Paul Griffin

Priority 2008-01-31 • Filing 2009-01-31 • Publication 2009-08-06

The present disclosure provides compositions and methods for the treatment and elimination of chronic intracellular infections in cells or organisms. The compositions may include one or more acidic substances and one or more antimicrobial substances, administered in combination or separately. The ...

73. Methods and systems for enhancing safety of psychedelic drug therapies

WO [WO2019079742A1](#) Shlomi RAZ Eleusis Benefit Corporation, Pbc

Priority 2017-10-19 • Filing 2018-10-19 • Publication 2019-04-25

The present invention provides methods and systems of enhancing the safety of psychedelic drug therapies (e.g., 5-HT2A agonists (e.g., LSD and **psilocybin**), dissociatives, and empathogens), for example, as part of a complex therapy. In particular, the invention features methods and systems for ...

74. 5-HT2C receptor agonists and compositions and methods of use

WO EP US CN JP KR AU BR CA EA MX EP3328835A1 Juerg Lehmann Arena Pharmaceuticals, Inc.

Priority 2015-07-31 • Filing 2016-07-28 • Publication 2018-06-06

Provided in some embodiments are compounds of Formula A, as defined herein, that modulate the activity of 5-HT2C receptor. Also provided in some embodiments are methods, such as, for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, ...

75. A medicament used for treating tumours

CN [CN108619214A](#) 王慎君 王慎君

Priority 2017-03-15 • Filing 2017-03-15 • Publication 2018-10-09

A medicament for treating tumors, characterized in that technical, tobacco acid content mood and boost the confidence of 1000mg / bag, **psilocybin** 30mg / bag, Rhodiola extract 500mg / package; purifying the blood lipoic acid content of 350mg / package, propolis content 1000mg / bag, pangamic acid I ...

76. 5-HT2C receptor agonists and compositions and methods of use

WO AU CA [AU2017313908A1](#) Michelle Kasem Arena Pharmaceuticals, Inc.

Priority 2016-08-19 • Filing 2017-08-18 • Publication 2019-02-28

The present invention relates to compounds of Formula A and pharmaceutical compositions thereof that modulate the activity of the 5-HT

77. Methods for treating dependence

AU [AU2014202047A1](#) Mark Moran Biotie Therapies, Inc.

Priority 2007-08-06 • Filing 2014-04-11 • Publication 2014-05-01

Provided are methods of treating patients suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at least one substance with Compound A. Also provided are methods of treating at least one phase of substance dependence on at least one substance in ...

78. Use of 3-methylmethcathinone

WO [WO2019026019A1](#) Ezekiel Golan Therapeutic Adjuncts Inc.

Priority 2017-08-03 • Filing 2018-08-02 • Publication 2019-02-07

The present invention relates to methods of drug-assisted psychotherapy with cathinone, particularly methods employing 3-methyl methcathinone (3-MMC). The present invention

also relates to kits comprising 3-MMC for use in the treatment of subjects undergoing psychotherapeutic intervention. In ...

79. A process for the recovery of indole derivatives from fungal mycelia and ...

DD DD265636A1 Jochen Gartz Akad Wissenschaften Ddr

Priority 1987-10-30 • Filing 1987-10-30 • Publication 1989-03-08

The invention relates to the microbial production of indole derivatives. It is applicable for the production of model substances for neurobiological and psychiatric examinations. The invention consists in the use of culture media, which consist of complex natural or synthetic substrates, each of ...

80. Combination product for the treatment of neurological and/or psychiatric ...

WO WO2019081764A1 Ana María PEREZ CASTILLO Consejo Superior De Investigaciones Científicas (Csic)

Priority 2017-10-26 • Filing 2018-10-26 • Publication 2019-05-02

The present application provides a combination product for the treatment and/or prevention of psychiatric and/or neurological disorders. The combination product comprises (i) a compound which promotes neurogenesis and has hallucinogenic and/or psychedelic side effects, and (ii) a 5-HT2A receptor ...

81. Compositions for the treatment of epistaxis

WO EP CN CA CN107073293A E·洛金斯基 托匹泰克以色列制药有限公司

Priority 2015-05-01 • Filing 2015-05-01 • Publication 2017-08-18

A topical composition includes at least one film forming agent; at least one surfactant; at least one non-polar volatile siloxane solvent; and a therapeutically effective concentration of at least one pharmaceutical agent selected from the groups comprising vasoconstrictors and antifibrinolytics, ...

82. A process for the recovery of indoles by culturing agaricales and breeding ...

DD DD266811A1 Jochen Gartz Akad Wissenschaften Ddr

Priority 1987-11-09 • Filing 1987-11-09 • Publication 1989-04-12

... recovery of indoles from fungal mycelia, wherein using cheap "natural raw materials cultivation under sterile conditions and at variable temperatures is effected, wherein the zusätzlcho Verfahrenschnitt the previous separation of the mycelia is omitted and largely constant yields of **psilocybin** to ...

83. A process for obtaining 4-substituted indole compounds

DD DD273449A1 Jochen Gartz Akad Wissenschaften Ddr

Priority 1988-06-29 • Filing 1988-06-29 • Publication 1989-11-15

The invention relates to the microbial production of 4-substituted indole compounds. It is applicable to the extraction of active ingredients for the experimental neurobiology. The invention consists in the use of solid media, which consist of mixtures of complex natural substrates, each of which ...

84. Assessing and treating psychedelic-responsive subjects

WO WO2018195455A1 Suzanne RUSS Eleusis Benefit Corporation, Pbc

Priority 2017-04-20 • Filing 2018-04-20 • Publication 2018-10-25

The invention features methods of identifying a subject as being likely to have a positive therapeutic response to a psychedelic agent. Methods of the invention also include administering a psychedelic agent to a subject (e.g., a subject that has been identified as likely to respond positively ...

85. Benzothiazole derivatives

WO EP US ES US8168785B2 Thomas R. Malefyt Biotie Therapies, Inc.

Priority 2009-06-17 • Filing 2009-06-17 • Grant 2012-05-01 • Publication 2012-05-01

Provided are compounds and their pharmaceutically acceptable salts that are useful for the treatment of diseases related to the adenosine receptor. Also included are methods of treating patients suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at ...

86. Utilizing the treatment of drug abuse pyrrolidine derivatives in the ...

WO EP US JP AR AU DE DK ES FR PT TW ZA JP2000504681A インペラート, アスンタ ローン—プラン・ロレ・ソシエテ・アノニム

Priority 1996-02-07 • Filing 1997-02-03 • Publication 2000-04-18

(57) Abstract: Pyrrolidine derivatives having general formula (I), their racemates if they contain one or more asymmetric centers and enantiomers, and their salts, other than alcohol abuse , use for the manufacture of a medicament intended for the treatment of abuse of substances causing drug or ...

87. A process for recovering tryptophan derivatives by culturing higher fungi

DD DD278600A1 Jochen Gartz Akad Wissenschaften Ddr

Priority 1988-12-23 • Filing 1988-12-23 • Publication 1990-05-09

The invention relates to the microbial production of tryptophan derivatives. It is applicable to the extraction of active ingredients for the experimental neurobiology and drug synthesis. The invention consists in the use of solid media consisting of substrates, may be added to the ...

88. Novel Gymnopilus luteofolius strain as well as cultivation method and ...

CN107771613A 胡惠萍 广东省微生物研究所

Priority 2017-10-25 • Filing 2017-10-25 • Publication 2018-03-09

The invention relates to a novel strain and an artificial cultivation method thereof and in particular relates to a novel Gymnopilus luteofolius strain as well as a cultivation method and

applicationof the novel *Gymnopilus luteofolius* strain. The novel *Gymnopilus luteofolius* strain is *Gymnopilus* ...

89. A process for recovering baeocystin by biotransformation of tryptamine

DD DD287053A5 Jochen Gartz Akademie Der Wissenschaften Der Ddr,De

Priority 1989-08-15 • Filing 1989-08-15 • Publication 1991-02-14

The invention relates to a process for the recovery of the active ingredient baeocystin by biotransformation of tryptamine means of basidiospores higher fungi. The substance can be applied as a pharmaceutical agent and as a model substance in the neurochemical basic research. After the inoculation ...

90. fungal mycelia process for the recovery of indole alkaloids from culture medium ...

DD DD255749A1 Jochen Gartz Akad Wissenschaften Ddr

Priority 1986-11-06 • Filing 1986-11-06 • Publication 1988-04-13

The invention relates to the microbial production of indole alkaloids. It is applicable for the preparation of model compounds for the experimental psychiatric research and for neurobiological studies. The invention consists in the use of a new nutrient medium, which is composed of synthetic and ...

91. Packaging of immunostimulatory oligonucleotides into virus-like particles: ...

WO EP US CN JP KR AU BR CA MX NZ RU ZA EP1605973B1 Martin F. Bachmann Cytos Biotechnology AG

Priority 2003-03-26 • Filing 2004-03-25 • Grant 2012-09-26 • Publication 2012-09-26

(g) methylenedioxymethamphetamine; (h) methamphetamine; (i) methylphenidate; (j) nicotine; (k) LSD; (l) mescaline; (m) **psilocybin**; and (n) tetrahydrocannabinol. The composition of any one of claims 1 to 6, wherein said antigen is derived from the group consisting of: (a) viruses; (b) bacteria; (c) ...

92. Library of cell collection

**WO EP US JP AT AU CA DE DK JP4965625B2 ゴールドスマス、ニールエボルバア
クチェンゲゼルシャフト**

Priority 2001-01-25 • Filing 2009-10-07 • Grant 2012-07-04 • Publication 2012-07-04

A library comprising a collection of individual cells, Each cell The following formula: (here, rs SP represents a spacer of at least two bases, X represents an expressible nucleotide sequence, PR denotes a promoter capable of controlling the expression of X in the cell, TR represents a terminator, ...

93. Collector composition and its methods for making and using same

WO US CN AU CA CL MA CN105792942B J·B·海因斯 佐治亚-太平洋化工品有限公司

Priority 2013-10-09 • Filing 2014-10-08 • Grant 2019-04-16 • Publication 2019-04-16

There is provided collector composition and its preparation and applied to the method for purifying one or more raw materials. Collector composition may include one or more amido amines with Formula I and the amine with Formula I V, and wherein amido amine and the weight ratio of amine can be about ...

94. Process for the manufacture of pharmaceutical compositions containing ...

EP JP AU CA DK ES ZA CA1246446A Rene Muntwyler Rene Muntwyler

Priority 1984-02-15 • Filing 1985-02-13 • Grant 1988-12-13 • Publication 1988-12-13

Abstract Process for the manufacture of pharmaceutical compositions containing unilamellar liposomes The present invention relates to a process for the maunfacture of pharmaceutical compositions in the form of aqueous dispersions containing unilammellar liposomes comprising (I) an amphiphatic ...

95. Safety of pseudoephedrine drug products

US US9421266B2 Clifford Riley King Pisgah Laboratories, Inc.

Priority 2007-05-22 • Filing 2012-12-21 • Grant 2016-08-23 • Publication 2016-08-23

Drug substances comprising a amine containing pharmaceutically active compound, and at least one of an alditol acetal and an aromatic organic acid as an addition salt or an additive.

96. Detection of metabolites for controlled substances

US US10254298B1 Chung-Yan Koh National Technology & Engineering Solutions Of Sandia, Llc

Priority 2015-03-25 • Filing 2015-12-02 • Grant 2019-04-09 • Publication 2019-04-09

The various technologies presented herein relate to identifying whether an individual has taken, and/or is under the influence of, a restricted drug. A density separation technique is utilized, wherein a sample (e.g., blood, saliva, urine, etc.,) which may include an analyte is exposed to a first ...

97. Mass produced, low cost, portable test kit for the detection and identification ...

US US9759733B1 Michael D. Callahan Michael D. Callahan

Priority 2016-04-08 • Filing 2016-04-08 • Grant 2017-09-12 • Publication 2017-09-12

A highly portable, paper and swab-based detection kit is provided for identifying Amphetamine, Cannabis, Cocaine, Heroin, selected synthetic Cannabinoid, and amphetamine based Cathinone type stimulants, and cannabis consumable products. A method of mass manufacture providing low cost kits with ...

98. Molecular antigen arrays using a virus like particle derived from the ap205 ...

WO EP US CN JP AT AU BR CA HK IL MX NZ RU ZA EP1532167B1 Martin F. Bachmann Cytos Biotechnology AG

Priority 2002-07-17 • Filing 2003-07-14 • Grant 2012-01-25 • Publication 2012-01-25

The present invention provides a composition comprising an AP205 virus like particle (VLP) and an antigen. The invention also provides a process for producing an antigen or antigenic determinant bound to AP205 VLP. AP205 VLP bound to an antigen is useful in the production of compositions for ...

99. Evolution methods to multiple parameters screening and multiple functional ...

WO EP US JP AT AU CA DE JP4472345B2 アレキサン德拉・エミ・ペ・サンタナ・ソエレンセン エヴォルヴァ・リミテッド Evolution Ltd.

Priority 2002-01-25 • Filing 2003-01-24 • Grant 2010-06-02 • Publication 2010-06-02

A method for evolving a cell producing at least one compound having two or more predetermined functionalities, the method comprising the steps of: a) at least one of each has said heterologous sequence of at least two heterologous expressible nucleotide sequences provides a cell composition ...

100. Concatemer of multiple genes differentially expressed

WO EP JP AT AU CA DE NZ JP5001346B2 ゴールドスマス, ニール エボルバ アク チェンゲゼルシャフト

Priority 2001-01-25 • Filing 2009-12-18 • Grant 2012-08-15 • Publication 2012-08-15

In the 5' → 3' direction, the general formula rs SP represents a spacer of the individual to at least two nucleotide bases, PR denotes a promoter X represents an expressible nucleotide sequence, TR represents a terminator, a n ≥ Nucleotide concatemer. Comprising a DNA sequence which nucleotide ...